4-(4-Fluorophenyl)-7-((4-formyl-1H-pyrazol-1-yl)methyl)quinoline-2-carboxamide → 7-({4-[Cyclopropyl(hydroxy)methyl]-1H-pyrazol-1-yl}methyl)-4-(4-fluorophenyl)quinoline-2-carboxamide
Reaction equation
[F:1][C:2]1[CH:7]=[CH:6][C:5]([C:8]2[C:17]3[C:12](=[CH:13][C:14]([CH2:18][N:19]4[CH:23]=[C:22]([CH:24]=[O:25])[CH:21]=[N:20]4)=[CH:15][CH:16]=3)[N:11]=[C:10]([C:26]([NH2:28])=[O:27])[CH:9]=2)=[CH:4][CH:3]=1.[CH:29]1([Mg]Br)[CH2:31][CH2:30]1>C1COCC1>[CH:29]1([CH:24]([OH:25])[C:22]2[CH:21]=[N:20][N:19]([CH2:18][C:14]3[CH:13]=[C:12]4[C:17]([C:8]([C:5]5[CH:6]=[CH:7][C:2]([F:1])=[CH:3][CH:4]=5)=[CH:9][C:10]([C:26]([NH2:28])=[O:27])=[N:11]4)=[CH:16][CH:15]=3)[CH:23]=2)[CH2:31][CH2:30]1Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Conditions
- Temperature
- 0 °C
Procedure
To a 0° C. solution of 4-(4-fluorophenyl)-7-[(4-formyl-1H-pyrazol-1-yl)methyl]quinoline-2-carboxamide (3-9, 36.0 mg, 0.0960 mmol, 1.0 equiv.) in anhydrous THF, under nitrogen was added dropwise 0.5 M cyclopropylmagnesium bromide in THF (0.769 mL, 0.385 mmol, 4.0 equiv.). The resulting mixture was stirred at 0° C. for 1 hour, quenched with sat. aqueous NH4Cl, extracted with ethyl acetate (3×5.0 mL), dried over MgSO4, filtered and concentrated. The residue was purified by reverse phase HPLC (H2O/CH3CN gradient w/0.1% TFA modifier) to afford 7-({4-[cyclopropyl(hydroxy)methyl]-1H-pyrazol-1-yl}methyl)-4-(4-fluorophenyl)quinoline-2-carboxamide (3-10, 25.0 mg, 62.4%) as a colorless solid. 1H NMR (400 MHz, CDCl3): δ 8.228 (s, 1H); 8.084 (br s, 1H); 7.995 (s, 1H); 7.929 (d, J=8.81 Hz, 1H); 7.625 (s, 1 μl); 7.515 (s, 1H); 7.442-7.506 (m, 3H); 7.206-7.249 (m, 2H); 5.777 (br s, 1 μl); 5.526 (s, 2H); 4.044 (d, J=8.48 Hz, 1H); 1.185-1.258 (m, 1H); 0.599-0.638 (m, 2H); 0.331-0.454 (m, 2H). LRMS m/z (M+H)+ 417.2 found, 417.2 required.
Workup
- customquenched with sat. aqueous NH4Cl
- extractionextracted with ethyl acetate (3×5.0 mL)
- dry with materialdried over MgSO4
- filtrationfiltered
- concentrationconcentrated
- customThe residue was purified by reverse phase HPLC (H2O/CH3CN gradient w/0.1% TFA modifier)
Sources & evidence
- ORD record
- ord-f31625cebc23491b8315621deb88d1ff
- Source dataset
- uspto-grants-2016_03
- Patent number
- US09278960B2
Reaction notes
Loading…